Premium
Anthranilic acid and 3‐hydroxyanthranilic acid, but not kynurenic acid, are associated with plasma pyridoxal‐5 phosphate levels
Author(s) -
Reginaldo Christina Dichoso,
Selhub Jacob,
Paul Ligi,
Jacques Paul,
Wang Thomas,
Gerszten Robert
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.1077.21
Subject(s) - kynurenic acid , kynurenine , anthranilic acid , kynurenine pathway , quinolinic acid , medicine , chemistry , pyridoxal , endocrinology , cofactor , framingham heart study , tryptophan , biochemistry , framingham risk score , enzyme , disease , amino acid
Both high inflammation and low pyridoxal 5′‐phosphate (PLP) status are associated with chronic diseases such as cardiovascular disease and diabetes. A hallmark of inflammation is the induction of indoleamine‐2,3‐dioxygenase (IDO) by the inflammatory cytokine interferon‐γ, leading to the degradation of tryptophan through the kynurenine pathway. Since PLP is a cofactor for many of the enzymes in the kynurenine pathway, we hypothesize that plasma PLP levels could modulate the formation of some of the kynurenines that require PLP as a cofactor for synthesis. To test this, a secondary data analysis was performed on metabolomics data from 1,868 subjects from Framingham Offspring cohort, Exam 5. Using generalized linear models, anthranilic acid (AA) and 3‐hydroxyanthranilic acid (OH‐AA) were found to be positively associated with PLP after adjusting for age, sex, BMI, creatinine, smoking status, and NSAID use (p=0.04 and 0.02, respectively). A 10 nmol/L increase in PLP status was associated with 0.5% and 1.1% increases in AA and OH‐AA, respectively. Kynurenic acid (KA) was not found to be associated with PLP (p = 0.41). Results suggest that AA and OHAA are weakly associated with plasma PLP. Supported by USDA cooperative agreement 51520–008‐045 and NHLBI Framingham Heart Study (Contract No.N01‐HC‐25195). Grant Funding Source : USDA cooperative agreement 51520–008‐045 and NHLBI Framingham Heart Study (Contract No.N01‐HC‐25195).